Role of Dashang Guggulu and Shatpuspha Churna in PCOD in Corporate Sector Women

A Nidanatmaka Survey Study and Randomized Comparative Clinical Trial of Dashang Guggulu and Shatpuspha Churna in PCOD in Corporate Sector Women

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/08/055990

Enrollment

Registered

2023-08-01

Start date

Unknown

Completion date

Unknown

Last updated

2023-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N74- Female pelvic inflammatory disorders in diseases classified elsewhere Health Condition 2: N948- Other specified conditions associated with female genital organs and menstrual cycle Health Condition 3: N948- Other specified conditions associated with female genital organs and menstrual cycle

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: Female patients of age group between 21 to 40 years (Both married and unmarried) Patient having two out of three criteria- ASRM/ESHRE (Rotterdam) Criteria,2018 Oligo and /or anovulation Hyperandrogenism (clinical and /or biochemical). Polycystic ovaries (Confirmed on USG) BMI >=23

Exclusion criteria

Exclusion criteria: ? Patient having any other disease causing oligomenorrhoea and anovulation excluding PCOD on above criteria. ? Any organic lesions of reproductive tract like T.B., carcinoma and congenital deformities or any other pelvic pathology. ? Patient suffering from hyperprolactinemia, adrenal hyperplasia, severe insulin resistance, androgen secreting neoplasm, thyroid abnormalities, Cushingâ??s syndrome, cardiac diseases will exclude. ? Current or previous (within last 3 months) use of OC pills, Glucocorticoids, anti-androgens, ovulation induction agents, anti-diabetic, anti-obesity drugs, or other hormonal drugs

Design outcomes

Primary

Measure	Time frame
Changes in Physical Measurement & biochemical investigations for Medodusthi Changes in serum LH & FSH value Change in USG Report & other laboratory investigations for Aartavdusthi. Timepoint: 90 Days	—

Secondary

Measure	Time frame
Changes in the Subjective Parameters of Medodusthi and AartavdusthiTimepoint: 90 Days	—

Countries

India

Contacts

Public ContactRashmi Temani

National Institute of Ayurveda

ssurendr452@gmail.com9414361874

Outcome results